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ABSTRACT 
Objective: The purpose of current study was to improve physicochemical properties such as micrometric, compressibility and solubility of linezolid 
(LNZ) by preparing crystallo-co-agglomerates (CCA) in the presence of polymer for the enhancement of overall physicochemical performance. 
Methods: The process of agglomeration involves the use of dichloromethane (DCM) as a good solvent and chloroform as bridging liquid were used 
to prepare agglomerates. Agglomerates were characterised in the solid state using several techniques such as Scanning electronic microscopy(SEM), 
Fourier transformation infrared spectroscopy (FTIR), X-ray powder diffraction analysis (XRPD) The agglomerates obtained were evaluated for 
micrometric, mechanical, deformation, compressibility and drug release properties. 
Results: It was found that micrometric properties and dissolution characteristics of agglomerates were significantly improved than that of pure 
linezolid. Solubility was found to be increased than pure linezolid. The solubility of crystallo co-agglomerates was found an increase in 5 fold 3 fold 
and 3.7 fold for PVPK30 (0.5%), PVPK30 (0.25%) and PVPK30 (0.75%) respectively. The angle of repose for all batches was found between 22 ° to 
30 °Carrs index was between 12.27±0.6 to 18.73±0.4 and Hausners ratio Near to 1, indicated good flow ability of agglomerates. The time required 
for drug release over a period of 60 min, is as LA1>LA2>LA3. LA3 shows fast drug release than LA1 and LA2, due to solubilization of drug due to 
more concentration of PVPK30 and less concentration of talc. 
Conclusion: Based on the above results, it was revealed that CCA of linezolid prepared with DCM and HPMC (Hydroxypropyl methyl cellulose)/PEG 
(Polyethylene glycol)/PVP (Polyvinylpyrrolidone) K30 exhibited improved micrometric properties, compressibility and in addition to improving 
solubility and dissolution rate. 
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The focus of today’s pharmaceutical industry is to better drug delivery 
concepts but also makes the simple standard formulations as 
economical as possible to produce. One of the most economical 
solutions is to find directly compressible formulations and this is 
especially at interest for large volume products. There is an interest in 
examining the potential of direct compression tabletting in recent 
years over traditional granulation process. Such manufacturing of the 
tablets involves simple mixing and compression of powders which 
gives benefits like time and cost saving [1]. Thus direct tabletting 
technique has been widely used successfully for various drugs. 
However, compressing a drug directly requires good micromeritic 
properties, such as flowability, good reproducible compression 
behaviour as it affects in vitro and in vivo performance of 
pharmaceuticals [2, 3], But it strongly depends upon the quality of the 
crystals used. To impart these properties the drugs are subjected to 
particle design techniques, spherical crystallization is one of the 
techniques of particle design [4, 5]. By this technique manufacturing 
process highly improved also a high degree of particle functionality is 
achieved [6]. 
In the pharmaceutical field, Kawashima et al. have given an impulse 
to the research of the spherical crystallization process. “Spherical 
crystallization” was defined by Kawashima as “an agglomeration 
technique that transforms crystals directly into a compacted 
spherical form during the crystallization process.” Spherical 
crystallization is a particle design technique which is restricted to 
only water insoluble single large dose drugs only because several 
excipients are hydrophilic in nature hence the addition of these 
excipients in the agglomerates with the help of organic bridging 
liquid is difficult [7]. Kadam et al. developed the CCA technique, 
which is a modification of spherical crystallization. CCA has been 
designed to overcome the limitations of spherical crystallization to 
obtain directly compressible agglomerates [8, 9]. Basically, it’s single 
step process used for size enlargement of single, two or more, small 
dose or large dose drugs, in combination with or without diluents. 
The process of CCA involves simultaneous crystallization and 
agglomeration of drug/s with/without excipients from the good 
solvent and/or bridging liquid by addition of a non-solvent [10, 11]. 
The tablet dosage form prepared from agglomerated crystals 
showed improvements in tensile strength, hardness, friability, 
disintegration time and dissolution rate as compared to tablets 
prepared from granules. Thus this technique of particle design of 
drugs has emerged as one of the areas of active research in 
pharmaceutical manufacturing which is simple, less expensive and 
advantages for developing it on a commercial scale for 
manufacturing of tablets gained great attention and importance 
due to the fact that crystal habit (form, surface, and size and 
particle size distribution) can be modified during the 
crystallization process [12, 13]. 
LNZ is poorly water soluble belong to Biopharmaceutical 
Classification System (BCS) Class IV drug. Generally inadequate 
solubility and dissolution rate are the problems associated with a 
stable crystalline form that results in poor oral absorption and less 
bioavailability. Nowadays crystallo-co-agglomeration technique has 
been attracting the attention of researchers for increasing the 
solubility, dissolution and micrometric properties of the drug [14, 
15]. The present study is an attempt to improve physicochemical 
properties such as micrometric properties, compressibility, 
solubility and or dissolution of LNZ using CCA technique. The choice 
of drug was made on the basis of significant compressibility and 
solubility problems associated with the drugs. CCA of LNZ prepared 
in the presence of polymer (hydrophilic carrier) for the 
enhancement of overall physicochemical performance. In this 
process, LNZ was crystallized from DCM as a good solvent and 
agglomerated with excipients in the presence of chloroform as 
bridging liquid. Physicochemical properties of raw LNZ and its 
agglomerates were characterized in the solid state using techniques 
such as SEM, FTIR, DSC, XRPD, solubility studies and dissolution test. 
The improvement in micromeritic properties was determined by 
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calculating the angle of repose, Hausner ratio, Carr’s index of LNZ 
and its agglomerates respectively.  
MATERIALS AND METHODS 
Material 
LNZ was obtained as a gift sample from Bharat Pharmaceuticals 
Thane, India. PEG 6000, PVP K30, Dichloromethane and Chloroform 
were procured from SD fine chemicals, Mumbai, India. All other 
chemicals and reagents used were of analytical grade 
Method 
LNZ and HPMC were dissolved in 25 ml DCM (good solvent) and 4 
ml chloroform (bridging liquid) and talc were uniformly dispersed in 
it. The resultant solution was poured into 50 ml of water containing 
PEG6000 and PVPK30 with stirring at 800 revolutions per min 
(rpm). The stirring was continued to obtain agglomerates, which 
were then filtered and dried overnight at room temperature. Above 
process was repeated more than 3 times to obtain adequate 
materials for characterization and to observe repeatability. 
Formulation codes with the proportion of excipients used for CCA of 
LNZ are as given in table 1. 
Saturation solubility studies 
Solubility studies were carried out in distilled water according to 
the method reported by Higuchi and Connors [16]. Excess 
quantity of LNZ and its prepared CCA were introduced in 20 ml 
of distilled water and shaken for 24 h at room temperature. The 
content of each flask was then filtered through a Whatmann 
filter paper. The filtrate was then diluted and assayed 
spectrophotometrically at 251 nm. Each solubility was 
determined in triplicate (n=3). The results obtained from 
saturation solubility studies were statistically analyzed.  
Where, L: linezolid, LA1: linezolid+talc (1:1), LA2 (linezolid+talc 
(1:0.75), LA3: linezolid+talc (1:0.5) 
 
Table 1: Formulation of linezolid CCA 
Ingredients LA1 LA2 LA3 
Linezolid 100 mg 100 mg 100 mg 
Talc 100 mg 75 mg 50 mg 
HPMC E50LV (%wt/wt of solids) 5.0% 5.0% 5.0% 
PEG 6000 (% w/w of solid) 6.0 % 6.0% 6.0 % 
PVP K30 (% w/w of drug) 0.25% 0.5% 0.75% 
 
Process yield and drug content 
The percent yield of the agglomerate was determined by applying the 
mass balance equation to the process. The drug content was determined 
for each batch separately in triplicate. For determination of drug content 
in agglomerates were powdered and from which powder equivalent to 
10 mg of linezolid was weighed from each batch and added to a solvent 
system containing DCM 10 ml and sonicated for 15 min. Appropriately 
diluted samples were filtered through whatman filter paper (pore size 
0.45 μm) and drug content was determined spectrophotometrically at 
251 nm for LNZ using UV-Visible spectrophotometer. The percentage 
drug content was calculated using following formula given below. All 
analyses were carried out in triplicate [17]. 
Percentage yield =
Total weight of agglomerate
Total weight of drug and polymer 
× 100---------(1) 




Scanning electron microscopy (SEM) 
The surface morphological properties of pure drug and CCA were 
investigated by scanning electron microscopy (SEM-Jeol Instruments, 
JSM-6360, Japan). Samples were mounted on a double-faced adhesive 
tape, sputtered with gold. Scanning electron photographs were taken at 
an accelerating voltage of 15 kV and obtained micrographs were 
examined at X2000, X5000, X10000 and X15000 magnifications.  
X-Ray powder diffractometry (XRPD) 
The XRPD data of pure drug and CCA were recorded on a Philips 
Analytical X-ray-PW 3710 (Phillips, Almedo, The Netherlands) 
diffractometer with tube anode Cr over the interval 10-70 °/2Ө 
under following a set of conditions: The generator tension (voltage): 
40 kV and generator current: 25 mA.  
Differential scanning calorimetry (DSC) 
DSC studies were carried out using Mettle-Toledo DSC 821 
instrument. Indium and zinc standards were used to calibrate 
the DSC temperature and enthalpy scale. A powdered sample 
was hermetically sealed in aluminium crucibles and heated at a 
constant rate of 10 °C/min over a temperature range of 25-250 
°C. Inert atmosphere was maintained by purging nitrogen gas at 
a flow rate of 50 ml/min. results were obtained in triplicates for 
each sample [18]. 
Fourier transformation infrared spectroscopy (FTIR) 
FTIR spectra of Pure drug obtained using a Shimadzu FTIR 
spectrometer (Agilent Technologies, carry 630 FTIR) spectrometer. 
The scanning range was kept from 4000 to 400 cm-1. Similarly, the 
spectra of polymers and physical mixtures were taken. 
Measurement of flowability 
Flowability of pure linezolid and their prepared agglomerates were 
determined in terms of angle of repose, Carr’s compressibility index 
and Hausner ratio. The angle of repose of drug powder and the 
agglomerates were assessed by fixed funnel method. The Carr’s 
index reflects the compressibility of the agglomerates and there is a 
correlation between the compressibility index and the flowability of 
the CCA. The results presented are mean±SD (n = 3). 
Pressure-tensile strength (σt) relationship  
Same data were used as to Pressure-relative density relationship study 
and force (F) measured required for fracturing the compacts determined 
by a Monsanto-type hardness tester. The data were subjected to tensile 
(σt) determination using following equation [19-21]. 
σt = 2F πDt⁄  ---------(3) 
Where, D and t are diameter and thickness respectively, of the 
compacts, used. 
Pressure-relative density relationship 
The compressibility behaviors of the agglomerates were studied 
using Heckel equation. Intact agglomerates (225±5 mg) of LA1, LA2, 
LA3 were compressed separately by using a hydraulic press (Spectra 
Lab, Mumbai, Maharashtra, India) having a 8 mm flat-faced punch 
and die set at pressures of 0.5, 0.7, 1.0, 1.2, 1.5and 3.0 tons for 1 min 
of dwell time. Lubrication of the die and punches was performed by 
a 1% wt/vol dispersion of magnesium stearate in acetone. Compacts 
were allowed to relax for 24 h at ambient conditions. The weight, 
diameter and thickness of the compacts were determined. The data 
were processed using following equation.  
  (1 1 − 	) =  + ⁄ ----- (4) 
Where D and P are the packing fraction and applied pressure 
respectively. K is Heckel constant equal to 1/3σo, σo is yield 
strength and 3σo is mean yield strength (MyP). A is constant. 
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The dissolution rate studies of LNZ alone and prepared 
agglomerates were performed in triplicate using a USP Type II 
dissolution apparatus paddle method (Lab India, Model Disso 2000 
Tablet dissolution test apparatus, Mumbai, India). Dissolution 
studies were carried out using 900 ml of phosphate buffer (pH 6.8) 
at 37±0.5 ˚C at 50 rpm. The volume of dissolution medium was 
adjusted to 900 ml by replacing each 5 ml aliquot withdrawn with 5 
ml of fresh phosphate buffer (pH6.8). The solutions were 
immediately filtered through a 0.45 µm membrane filter, suitably 
diluted and the concentrations of linezolid in samples were 
determined spectrophotometrically at 251 nm. The results of 
dissolution studies were statistically analyzed.  
Release kinetics of LNZ from the compact. Intact agglomerates 
(225±5 mg) of LA1, LA2 and LA3 were weighed and compressed by 
a hydraulic press having a 8 mm flat-faced punch and die set at 4 
tons of pressure for 1 min of dwell time. The compacts obtained 
were subjected to dissolution in triplicate, similar to that of 
agglomerates. Each time, 5 ml of sample was withdrawn and 
analyzed spectrophotometrically at 251 nm. The same amount of 
fresh phosphate buffer (pH6.8) was used to replace the amount 
withdrawn. 
RESULTS AND DISCUSSION 
The performance of the CCA process was evaluated on the basis of 
ease of processing, agglomeration yield, and agglomerate handling 
qualities. All these process performance characteristics were 
observed in LA1, LA2 and LA3 batches. 
Saturation solubility studies 
Table 2 shows results of saturation solubility studies. The solubility of 
CCA was found to be increased than pure LNZ. There was 5 fold 
increase in case of PVPK30 (0.5%), there was 3 fold while in PVPK30 
(0.25%) and in PVPK30 (0.75%) ratio it was found to be 3.7 fold. The 
increment in solubility by crystallo-co-agglomeration was found to be 
a significant one. This might be due to changes in crystal habit, 
structure and surface morphology [21]. In addition to that, the solvent 
included in crystal form solvates that might have changed the 
reactivity of drug particles, surface morphology and internal energy of 
the molecules which would be responsible for increasing solubility of 
agglomerates [22]. 
 
Table 2: Saturation solubility of pure Linezolid and crystallo-co-agglomerates 





Results are mean of three determination±SD 
 
Process yield  
For LA1, LA2 and LA3, the yield of agglomeration was76.85±1.80% 
w/w, 69.83±0.92% w/w and 69.23±0.98% w/w respectively. The 
drug content of agglomerates was 89.90±0.60% w/w, 94.30±1.25% 
w/w, 96.20±0.99 % w/w for LA1, LA2 and LA3, respectively. It was 
greater in the initial stages but later got reduced because of 
entrapment of HPMC during the progress of agglomeration. 
  
Table 3: Actual yield, drug content and entrapment efficiency of crystallo-co-agglomerates of linezolid 
S. No. Batch code Yield (%) Drug content (%) 
1 LA1 76.85±1.80 89.90±0.60 
2 LA2 69.83±0.92 94.30±1.25 
3 LA3 69.23±0.98 96.20±0.99 
 Results are mean of three determination±SD 
 
Measurement of particle size distributions is routinely carried out 
across a wide range of industries and is often a critical parameter in 
the manufacture of many products. Mean particle size of linezolid was 
determined by randomly counting average diameter of 100 particles 
with an optical microscope (microscopy method). It was found that 
particle size of plane crystals and crystals with additives was increased 
than original crystals may be due to particle crystallisation is shown in 
table 4 [23]. The presence of DCM at the surface of the growing 
agglomerate, the agitation force, winter particulate attraction, and 
polymers (Talc, PEG and HPMC) influenced the size of agglomerates, as 
reported in earlier studies [16].  
More linezolid loading in LA3 decreased the cohesive attraction, 
reducing the size of agglomerates, and the presence of HPMC 
increased the size of agglomerates because of increased viscosity of 
DCM. Here, increased viscosity reduced the destructive forces acting 
on the agglomerates. PEG, because of its tendency to reduce interfacial 
tension, is reported to generate smaller agglomerates [24, 25]. 
Lalla and Bhat have reported an angle of repose of 22 ͦto 30ͦ for a 
spheronized product [26]. Hence, the observed angle of repose for 
all batches in the range of 22 ͦto 30 ͦindicated good flowability of 
agglomerates.
  
Table 4: Micromeritic properties of linezolid agglomerates 
S. No. FC* Diameter 
(μm) n=100 
Angle of 













































*FC: Formulation Code, Results are mean of three determination±SD, 
 i.e. FTIR study of the drug and agglomerates showed all the peaks of the drug as shown in fig. 1,2. 
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Fig. 1: FTIR spectra of standard linezolid 
 
 
Fig. 2: Drug and excipients compatibility study 
 
SEM gives information about the surface morphology of 
untreated pure drug and agglomerates. The pure drug in crystal 
needlelike while agglomerates show spherical structure as 
shown in fig. 3, fig. 4. 
 
 
Fig. 3: Scanning electron microscopy of linezolid pure drug. 
 
 
Fig. 4: Scanning electron microscopy of optimised batch of crystall-Co-agglomerates 
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XRPD study is required for determination of crystal lattice and 
amorphous nature of drug or excipients. By using XRPD we can measure 
the average spacing between layers or rows of atoms, determine the 
orientation of a single crystal or grain. The XRPD study of pure linezolid 
shown in fig. 5. It reveals that the intensity of the peaks for the pure drug 
was showed sharp distinct peaks notably at 2 °θ diffraction angles of 
8.14 °, 12.15 °, 16.38 °, 18.46 °, 21.05 °, 23.53 ° and 29.14 ° which indicate 
crystalline nature of pure drug. But when LNZ was incorporated into the 
polymers, after the preparation of agglomerates the intensities of the 
peaks decreases due to the decreased crystallinity of the LNZ in 
agglomerate form (fig. 5). This was because of dilution with polymers 
and dilution carried out by the PVPK30 though the intensity of peaks in 
XRPD was reduced, there is no considerable change in d-spacing values 
suggesting no change in crystal form of drug but crystal habit of the drug 
might be changed thus suggesting the absence of a polymorphic 
transition. How theta ever, no obvious peaks representing crystals of 
LNZ were seen for the solid spherical crystals, indicating the absence of a 
crystalline structure of LNZ in the formulation. 
 
 
Fig. 5: X-ray powder diffraction pattern of pure linezolid and optimized batch 
 
The DSC thermogram of pure LNZ showed sharp melting endotherm at 
180 °C with the heat of fusion-120 J/g. This clearly indicates crystalline 
nature of the pure drug. In the thermogram of the agglomerates 
showed a broad endothermic peak at the 178 °C which corresponds to 
a loss of water and shifting peak indicating hygroscopic nature of 
agglomerates. These findings indicated that raw crystals of LNZ have 
changed for agglomerates during recrystallization Thus DSC results 
were well supported with XRPD indicating the polymorphic transition 
of LNZ during recrystallization (fig. 5.6). This clearly indicated 
crystalline nature of the agglomerates. This observation also 
confirmed the absence of any chemical interaction of the drug with 
additives during agglomeration process, further supporting the results 
of IR spectroscopy. (fig. 1, fig. 2). 
Compression studies on agglomerates of LA1, LA2 and LA3 showed 
deformation of agglomerates instead of a fracture because the 
agglomerates had lower voids (porosity) showing interarticular 
slippage during compression. HPMC contributed to deformation of 
the agglomerates. Along with HPMC adsorbed at the surface of talc, 
high talc content also imparted deformability to agglomerates. The 
LA1 agglomerates required more deformation force than did the LA2 
and LA3 agglomerates, in agreement with the study performed by 
Pawar et al.[3]. The consolidation ability of agglomerates is indicated 
by Mean yield pressure (MyP). In the case of for LA2, LA3 MyP was 
less than LA1, and high pressure required to deformation of LA1 
(table 5). An increase in the talc percentage increased the 
deformation force. Tensile strength (σt) determine the ability of 
solid which withstand fracture. LA1 has high tensile strength than 
LA2, LA3, this indicates the bonding between talc and drug molecule 
more in LA1 (table 6). 
 
 
Fig. 6: DSC thermogram of linezolid and optimized batch 
 
Table 5: Compression properties of agglomerates 
S. No. Batch code Slope (Ky) MyP 
1 LA1 1.023 0.977 
2 LA2 1.743 0.679 
3 LA3 1.685 0.593 
 
Table 6: Pressure-tensile strength (σt) relationship data 
S. No. Pressure in Tons Tensile Strength(σt) 
LA1 LA2 LA3 
1 0.5 11.357 10.708 10.993 
2 0.7 11.804 11.301 11.194 
3 1.0 12.210 11.673 11.819 
4 1.2 12.590 12.614 12.760 
5 1.5 12.712 12.485 12.361 
6 3.0 13.292 12.532 12.452 
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The release of drug from agglomerates was more than 75.00%, 
within 60 min. 75.71±2.69%, 86.88±3.31%and 90.88±2.54% drug 
was released from agglomerates LA1, LA2 and LA3 respectively. 
Whereas from compacts prepared of agglomerates more than 
67.00%, within 60 min.67.11±2.69%, 86.02±2.88 and 90.62±2.84 
drug was released from compacts LA1, LA2 and LA3 respectively. 
The time required for drug release over a period of 60 min, is as 
LA1>LA2>LA3. LA3 shows fast drug release than LA1 and LA2, due 
to solubilization of drug due to more concentration of PVPK30 and 
less concentration of talc the data were expressed as mean±SD 
where n = 3(fig. 7, 8.). In this case, it was clearly evident that talc was 
not the sole factor retarding drug release (LA1). Predominantly, the 
extent of drug-diluents bonding in the compact (σt) determined the 
release of the drug. This indicates that there was a strong drug-
diluent (talc) interaction and amount of HPMC in the compact. Use of 
talc in the system retarded the release of the drug because of talc’s 
hydrophobic nature. 
Very few researchers have prepared miniscular dosage forms by 
using excipients with a large surface area [27, 28]. Pawar et al. 
designed a miniscular dosage form for ibuprofen-talc byCCA. Mainly, 
recrystallization of the drug during agglomeration generates the 
miniscular dosage form. The miniscular dosage form of Linezolid-
talc in this new study showed sustained drug release fitting the 
Higuchi matrix model, whereas sustained zero-order drug release 
was reported for ibuprofen-talc [29]. 
 
 
Fig. 7: Drug release study from agglomerates, Results are mean of three determination±SD, Where, LA1: linezolid+talc (1:1), LA2 
(linezolid+talc (1:0.75), LA3: linezolid+talc (1:0.5) 
 
 
Fig. 8: Drug release study from compressed tablet of agglomerates, Results are mean of three determination±SD, Where, LA1: 
linezolid+talc (1:1), LA2 (linezolid+talc (1:0.75), LA3: linezolid+talc (1:0.5) 
 
CONCLUSION 
The present study revealed that CCA of LNZ prepared with DCM and 
HPMC/PEG/PVP K30 exhibited improved micrometric properties, 
compressibility and in addition to improving solubility and 
dissolution rate. This technique might be applicable for producing 
oral solid dosage forms of LNZ with improved compressibility, 
solubility and dissolution rate. Thus instead of preparation of 
granules, the formation of agglomerates of linezolid would be 
expected to modify and improve physicochemical, bio-
pharmaceutical and tabletting properties. 
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